Q-omics provides the consensus-scored FAM90A26 profile across patient tissues and cancer cell-line models. FAM90A26 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, FAM90A26 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, FAM90A26 RNA expression shows 8,266 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, LUAD, and TGCT as cancer lineages where FAM90A26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM90A26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM90A26 survival associations across molecular data types. FAM90A26 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM90A26 RNA expression–survival associations across cancer types. High FAM90A26 expression shows unfavorable associations in COAD, BRCA, KICH, DLBC and KIRC, but favorable associations in LGG. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for FAM90A26 RNA expression.
This table summarizes FAM90A26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM90A26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM90A26 shows higher tumor expression in LUAD, CHOL and LUSC. The LUAD box plot shows higher FAM90A26 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .012).
This table shows molecular features associated with FAM90A26 in patient tissues and cancer cell lines. In patient samples, FAM90A26 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM90A26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS.
